Navidea Biopharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This dashboard includes a questions and answers table on Navidea Biopharmaceuticals Inc. If you are employed by Navidea Biopharmaceuticals Inc and you would like to licence your ESG rating, please get in touch. This ESG score for Navidea Biopharmaceuticals Inc indicates its transparency towards the UN Sustainable Development Goals.
Navidea Biopharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 5.3, social score of 3.2 and governance score of 8.0.
5.5
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
602 | SkinBioTherapeutics PLC | 5.6 | High |
602 | XOMA Corp | 5.6 | High |
627 | Navidea Biopharmaceuticals Inc | 5.5 | High |
627 | Advanced Medical Solutions Group PLC | 5.5 | High |
627 | Achieve Life Sciences Inc | 5.5 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Navidea Biopharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Navidea Biopharmaceuticals Inc disclose current and historical energy intensity?
Does Navidea Biopharmaceuticals Inc report the average age of the workforce?
Does Navidea Biopharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Navidea Biopharmaceuticals Inc disclose its ethnicity pay gap?
Does Navidea Biopharmaceuticals Inc disclose cybersecurity risks?
Does Navidea Biopharmaceuticals Inc offer flexible work?
Does Navidea Biopharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Navidea Biopharmaceuticals Inc disclose the number of employees in R&D functions?
Does Navidea Biopharmaceuticals Inc conduct supply chain audits?
Does Navidea Biopharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Navidea Biopharmaceuticals Inc conduct 360 degree staff reviews?
Does Navidea Biopharmaceuticals Inc disclose the individual responsible for D&I?
Does Navidea Biopharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Navidea Biopharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Navidea Biopharmaceuticals Inc disclose water use targets?
Does Navidea Biopharmaceuticals Inc have careers partnerships with academic institutions?
Did Navidea Biopharmaceuticals Inc have a product recall in the last two years?
Does Navidea Biopharmaceuticals Inc disclose incidents of discrimination?
Does Navidea Biopharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Navidea Biopharmaceuticals Inc issued a profit warning in the past 24 months?
Does Navidea Biopharmaceuticals Inc disclose parental leave metrics?
Does Navidea Biopharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Navidea Biopharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Navidea Biopharmaceuticals Inc disclose the pay ratio of women to men?
Does Navidea Biopharmaceuticals Inc support suppliers with sustainability related research and development?
Does Navidea Biopharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Navidea Biopharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Navidea Biopharmaceuticals Inc involved in embryonic stem cell research?
Does Navidea Biopharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Navidea Biopharmaceuticals Inc disclose its waste policy?
Does Navidea Biopharmaceuticals Inc report according to TCFD requirements?
Does Navidea Biopharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Navidea Biopharmaceuticals Inc disclose energy use targets?
Does Navidea Biopharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Navidea Biopharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Navidea Biopharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.